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Abstract
A placebo-controlled phase 3 trial demonstrated that the epidermal growth factor receptor (EGFR) inhibitor erlotinib
in combination with gemcitabine was especially efficient in a pancreatic ductal adenocarcinoma (PDAC) subgroup of
patients developing skin toxicity. However, EGFR expression was not predictive for response, and markers to char-
acterize an erlotinib-responding PDAC group are currently missing. In this work, we observed high erlotinib IC50
values in a panel of human and murine PDAC cell lines. Using EGFR small interfering RNA, we detected that the
erlotinib response was marginally influenced by EGFR. To find novel EGFR targets, we used an unbiased chemical
proteomics approach for target identification and quality-controlled target affinity determination combined with
quantitative mass spectrometry based on stable isotope labeling by amino acids in cell culture. In contrast to
gefitinib, we observed a broad target profile of erlotinib in PDAC cells by quantitative proteomics. Six protein kinases
bind to erlotinib with similar or higher affinity (Kd = 0.09-0.358 μM) than the EGFR (Kd 0.434 μM). We provide
evidence that one of the novel erlotinib targets, ARG, contributes in part to the erlotinib response in a PDAC cell
line. Our data show that erlotinib is a multikinase inhibitor, which can act independent of EGFR in PDAC. These
findings may help to monitor future erlotinib trials in the clinic.
Neoplasia (2011) 13, 1026–1034
Introduction
The epidermal growth factor (EGF)/ErbB family of transmembrane
tyrosine kinase growth factor receptors include the EGF receptor
(EGFR/ErbB1), Her2/ErbB2, ErbB3, and ErbB4. Ligand-induced
homodimeriziation or heterodimeriziation induces autophosphoryla-
tion of EGFR, recruitment of signaling intermediates, and activation
of pathways such as Ras-ERK, phosphoinositide-3 kinase, Src, and
STAT. Dysregulated expression and signaling of the EGFR, mediated
by various mechanisms, is a common feature of solid cancers [1–3].
Several studies reported high expression of the EGFR, ranging from
7.7% to 100% of pancreatic ductal adenocarcinomas (PDACs) [4,
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and, referent herein, therein]. Subsequently, the orally active small-
molecule EGFR inhibitor erlotinib was the first drug approved by the
US Food and Drug Administration for the treatment of advanced PDAC
in combination with gemcitabine. The quinazolin derivative erlotinib
(OSI-774) competes with ATP for binding to the catalytic domain of
the EGFR, disrupting downstream signal transduction [5]. In a ran-
domized, double-blind, placebo-controlled phase 3 trial, erlotinib plus
gemcitabine was shown to be superior to gemcitabine monotherapy in
patients with advanced or metastatic PDAC [6]. Although the median
survival in the erlotinib plus gemcitabine arm (6.24 months) was only
marginally better than gemcitabine monotherapy (5.91 months; hazard
ratio = 0.82, P = .038), the combination was especially efficient in a sub-
group of patients developing erlotinib-induced skin toxicity grade 2 or
higher [6]. Despite the clear increase of the median survival in this par-
ticular subgroup to 10.5 months, EGFR expression levels were not pre-
dictors of response, arguing for the contribution of erlotinib off-targets.
Materials and Methods
Compounds
Erlotinib hydrochloride salt (Tarceva, OSI-774), imatinib methane-
sulfonate salt (Gleevec, STI-571), and gefitinib free base (Iressa,
ZD1839) were purchased from LC Laboratories (Woburn, MA).
Generation and Culture of PDAC Cells
Primary dispersed murine pancreatic cancer cells were established
from a genetically engineered KrasG12D-based mouse model of pan-
creatic cancer and cultivated as recently described [7,8] (see Table W1
for a detailed description of the murine PDAC cells used). Primary dis-
persed human PDAC cells, Technical University Munich Pancreatic
Cancer cells (TUM-PaCa3), were isolated from a primary PDAC
(G2, pT4, pN1 [6/12]). Excess tumor tissue not needed for diag-
nostics from a surgically resected PDAC was placed into chilled sterile
RPMI 1640 (HyClone, Logan, UT) supplemented with 1% (vol/vol)
penicillin/streptomycin/amphotericin B (P/S/A; Invitrogen,Darmstadt,
Germany). The tumor was washed twice, dissected into 1-mm cubes,
and digested in RPMI 1640 medium supplemented with 15% fetal
calf serum (Biochrome, Berlin, Germany), 1% (vol/vol) P/S/A, and
200 U/ml collagenase Type IV (Worthington Biochemical, Lakewood,
NJ) at 37°C for 24 hours. Dispersed TUM-PaCa3 cells were subse-
quently pelleted by centrifugation and cultured in RPMI 1640medium
(15% fetal calf serum, 1% [vol/vol] P/S/A). Only low-passaged (pas-
sages 3 and 4) dispersed TUM-PaCa3 cells were used for assays. Use
of tumor specimens was approved by the local ethical committee, and
patients provided signed informed consent. Human pancreatic cancer
cell lines were cultivated as recently described [9–11].
Small Interfering RNA Transfection and Cell Viability Assays
Small interfering RNA (siRNA) were transfected as recently de-
scribed [12], and the following targeting sequences were used: human
EGFR 5′ G G C A C G A G T A A C A A G C T C A 3′, murine
EGFR 5′ C A G A G G A C A A C A T A G A T G A 3′, human
ARG 5′ C G G T C A G T A T G G A G A G G T T 3′, murine
ARG 5′ C T A C C A C T G T T G T C A A G T A 3′, and control
siRNA 5′CAGTCGCGTTTGCGACTGG 3′. Cell viability
was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assays as described [8,9]. All data were obtained from
at least three independent experiments performed in triplicate, and the
results are presented as the mean and SEM.
Total Cell Lysates, Western Blots, and Immunoprecipitations
Whole-cell lysates were prepared, andWestern blots were carried out
as recently described [8,9]. The following antibodies were used: EGFR
(sc-03), control IgG and ARG (sc-6356; Santa Cruz Biotechnology,
Santa Cruz, CA), antiphosphotyrosine (clone 4G10;Millipore, Billerica,
MA), and β-actin (Sigma-Aldrich, Munich, Germany). Western blots
were performed using Odyssey Infrared Imaging System (LI-COR Bio-
sciences, Bad Homburg, Germany) as described [8,9]. For immuno-
precipitations (IPs), cells were lysed in RIPA buffer (150 mM NaCl,
1% IGEPAL CA-630, 0.5% sodium deoxycholate, 0.1% SDS,
50 mM Tris, pH 8, 0.1 mM phenylmethanesulfonylfluoride
[PMSF]), and IPs were performed as recently described [11]. To quan-
tify EGFR and ARG protein expression, the ratio of EGFR/β-actin
and ARG/β-actin was determined using the Odyssey Infrared Imaging
System, which assures measurements in the linear range. MiaPaCa2
cells served as a reference cell line, blotted on each membrane. The rel-
ative expression of EGFR and ARG was calculated by setting the EGFR/
β-actin and ARG/β-actin ratio determined in MiaPaCa2 arbitrary to 1.
Compound Synthesis and Immobilization, In Vitro Association
Experiments, Mass Spectrometric Analysis, and Data Analysis
Compound synthesis, stable isotope labeling by amino acids in
cell culture (SILAC), in vitro association experiments and mass spectro-
metric analysis were reported [13–17] and described in detail in
Supplemental Materials and Methods.
Statistical Methods
A two-tailed Student’s t test was used to test statistical significance.
P values are indicated and an asterisk (*) denotes a P value of less
than .05. The half-maximal inhibitory concentration (IC50) values
were calculated with GraphPad Prism4 software (La Jolla, CA) using
a nonlinear regression model with classic equations as described [9].
Results
To determine the sensitivity of primary murine and human PDAC
cells and established human PDAC cell lines to erlotinib, the viability
of cells treated with increasing concentrations of erlotinib (6, 12, and
18 μM) for 48 hours was measured in MTT assays to calculate the
IC50. Confirming recent observations [18–21] and compared with
peak plasma levels measured in patients [22,23], we detected quite
high IC50 values for erlotinib in human and murine PDAC cells;
the most sensitive cells showed IC50 values greater than 10 μM (Fig-
ure 1A and Table 1). Mean IC50 values of murine cells, established
from KrasG12D-dependent PDACs, and established human PDAC
cell lines were not significantly different (Figure 1B), indicating that
primary dispersed low-passaged murine cell collections are a valid plat-
form for the investigation of PDAC drug responses. Furthermore, low-
passaged dispersed TUM-PaCa3 cells established from a primary
human PDAC exhibits an IC50 in the range of established human
PDAC cell lines, suggesting that the observed high IC50 values are
not influenced by higher passage numbers and clonality of conventional
human PDAC cell lines. Interestingly, the EGFR protein abundance
was not correlated with the IC50 levels for erlotinib (Figure 1, C and
D), arguing that erlotinib might act independent of EGFR.
To investigate the impact of the EGFR for pancreatic cancer cell
viability and the therapeutic response toward erlotinib directly, we
used an EGFR-specific siRNA. Whereas a slight decrease of cell
viability on the EGFR knockdown was observed in MiaPaCa2 and
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BxPc3 cells, depletion of EGFR did not influence the viability of
human T3M4 or murine PPT6554 cells (Figure 2, middle panel ).
Surprisingly, the erlotinib response was quite similar, irrespectively of
EGFR depletion (Figure 2, right panel ). Together, these data suggest
that off-targets beyond EGFR may contribute to the erlotinib response
in PDAC cells.
To find possible novel erlotinib targets, we used an unbiased chemi-
cal proteomics approach for target identification and quality-controlled
target affinity determination using quantitative mass spectrometry
based on SILAC [14]. Primary dispersed murine PPT6554 cells were
used because it is one of the more erlotinib-sensitive lines. In the addi-
tion to some nonkinase proteins (Figure 3A, green), we identified sev-
eral kinases (Figure 3A, blue and purple) and kinase-associated proteins
(Figure 3A, orange) bound with high affinity by erlotinib. Importantly,
six kinases, namely, the serine/threonine protein kinase 10 (STK10/
LOK), themitogen-activated protein kinase kinase kinase 1 (MAP3K1),
the integrin-linked kinase (ILK), the STE20-like serine/threonine–
protein kinase (SLK), the receptor-interacting serine/threonine–protein
kinase 2 (Ripk2), and the tyrosine-protein kinase ARG (abelson-related
gene; ABL2), revealed even higher binding affinity to erlotinib than
EGFR (dissociation constant [Kd] = 0.434 μM). Here, Kd values rang-
ing from 0.09 to 0.358 μM were determined, respectively (Figure 3A
Figure 1. Erlotinib IC50 values of murine and human PDAC cells. (A) Viability of PDAC cells after treatment with 6, 12, and 18 μM erlotinib
was measured by MTT assay and compared to vehicle-treated controls. IC50 values of murine (black) and human (red) PDAC cell lines
were calculated using a nonlinear regression model. Statistics can be found in Table 1. (B) Mean IC50 values of murine (black triangle)
and human (red square) PDAC cell lines show no statistically significant differences (Student’s t test, P = .15). (C) Western blot analysis
of EGFR expression levels in the indicated PDAC cell lines. β-Actin controls equal protein loading. (D) Correlation of the erlotinib IC50
values with EGFR protein expression levels in 22 PDAC cell lines. The Spearman correlation coefficient and the P value (two-tailed)
are indicated.
Table 1. Response of Murine and Human PDAC Cell Lines to Erlotinib.
Cell Line IC50 (48 h) (μM Erlotinib) 95% CI
Human PDAC cells
PaTu8988t 12.3 9.9-15.4
BxPc3 21.9 17.1-28
MiaPaCa2 23.7 19.7-28.5
TUM-PaCa3 23.9 19.2-29.8
T3M4 37.3 29.7-46.9
HS766T 39.6 34.8-45
DanG 47.4 37-60.7
Panc1 62.6 53.3-72.1
Murine PDAC cells
W22 11.3 10.1-12.7
PPT6554 13.7 11.8-15.8
PPT6558 17.6 15.8-19.6
PPT6556 18.1 13.6-24.3
PPT15272 21.0 17.2-25.7
PPT16992 38.8 32.2-46.8
PPT53631 41.7 30.9-56.2
PPT6051 48.1 34.8-66.5
PPT2-3202 51.6 36.9-72.3
PPT53268 53.3 29.1-97.9
W30 62.4 44.7-87
PPT5436 68.2 49.6-93.7
PPT3107 77.4 47.2-126.9
ASC53909 132.3 92.0-190.0
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and Table W2). To compare the target profiles of different EGFR in-
hibitors, we performed the same experiment using the small-molecule
EGFR inhibitor gefitinib, which binds with similar affinity to the EGFR
(Kd = 0.323 μM) in PPT6554 cells (Figure 3B). Only one kinase, Ripk2
(Kd = 0.155 μM), was bound by gefitinib with a higher affinity than
the EGFR. Whereas gefitinib binds only three kinases with a high
affinity (Kd < 1 μM), erlotinib targets 11 protein kinases (Figure 3 and
TableW2). These data clearly demonstrate that erlotinib is a multikinase
Figure 2. Erlotinib response of PDAC cells is EGFR independent. MiaPaCa2 (A), BxPc3 (B), T3M4 (C), and PPT6554 (D) cells were trans-
fected with a control siRNA or an EGFR-specific siRNA. Left panel: Knockdown of the EGFR 48 hours after the transfection byWestern blot
analysis. β-Actin controls equal protein loading. Twenty-four hours after transfection, cells were treated with increasing doses of erlotinib as
indicated for 48 hours or were left as an untreated control. Viability was determined using MTT assays. Middle panel: Viability of control
siRNA-transfected cells was arbitrarily set to 100% and compared to (I) control siRNA-transfected and erlotinib-treated cells, to (II) EGFR
siRNA-transfected cells, and to (III) EGFR siRNA-transfected and erlotinib-treated cells. Right panel: Erlotinib-induced therapeutic response
in control and EGFR siRNA-transfected cells. Note that the right panels rely on an extrapolation of the data presented in the middle panels
to better visualize the erlotinib-induced loss of viability (=therapeutic response) in control and EGFR siRNA-transfected cells. Student’s
t test, *P < .05 versus controls.
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inhibitor in PDAC cells. A complete list of erlotinib and gefitinib targets,
including sequence coverage, binding curves, competition curves, andK d
values, can be found in Table W2.
In excellent work using a patient-derived xenotransplant model,
Jimeno et al. [19] described 25 genes defining a core enrichment gene
set linked to EGFR inhibitor sensitivity. Because ARG was included in
the gene set and was found to bind to erlotinib (Figure 3), we tested
whether ARG was involved in the erlotinib response of pancreatic can-
cer cells. Knockdown of ARG resulted in a statistically significant loss
of viability in human PDAC cells (Figure 4, middle panel ). No change
in viability after the ARG knockdown was observed in murine
PPT6554 cells. Erlotinib responsiveness remained unchanged in
BxPc3 and PPT6554 cells after ARG knockdown (Figure 4, right
panel ). In contrast, erlotinib evoked a distinct impaired response in
T3M4 and MiaPaCa2 cells after ARG knockdown (Figure 4, right
panel). Especially in T3M4 cells, the therapeutic response was ARG-
dependent at low erlotinib concentrations, suggesting that ARG con-
tributes to the erlotinib response in at least a subset of PDACs. The
ARG kinase is activated by autophosphorylation at several sites [24].
We observed a reduced tyrosine phosphorylation of ARG in response
to erlotinib in T3M4 cells (Figure 5A), which further confirms that
ARG is targeted by erlotinib. However, ARG protein abundance
was not correlated with IC50 values in the pancreatic cancer cell lines
investigated (Figure 5, B and C ), indicating that additional mecha-
nisms and considerable high tumor heterogeneity exists in PDAC. In-
deed, recent work shows that at least three distinct subtypes of PDAC
exist with distinct clinicopathologic and molecular features [25].
ABL as well as ARG kinase activities were shown to be equally in-
hibited by imatinib [24]. However, T3M4 cells are not characterized
by a particular imatinib sensitivity (Figure 5, D–G ), which is consis-
tent with the observation that only approximately 20% to 25% of the
viability of T3M4 cells is controlled by ARG (Figure 4C).
Discussion
Recent sequence analysis of PDAC has uncovered mutations of genes
in 12 core signaling pathways, demonstrating that PDAC is a geneti-
cally complex disease [26]. This complexity contributes to interindivid-
ual tumor heterogeneity and is reflected in the therapeutic effectiveness
of the EGFR inhibitor erlotinib. Only a subset of patients responds to
the erlotinib/gemcitabine combination therapy illustrating the need
for markers to identify patients most likely to benefit from treatment.
Currently, no such markers to predict response to erlotinib treatment
in PDAC are available. Furthermore, the level of EGFR expression
does not correlate with therapeutic response because the erlotinib/
gemcitabine combination is equally efficient in patients who express
EGFR as those who do not [6]. Consistently, EGFR amplification
and response toward combined erlotinib/gemcitabine therapy were
recently investigated using fluorescence in situ hybridization analysis
and demonstrated no predictive value of EGFR amplifications [27].
These observations together with our data, demonstrating that the
erlotinib response is marginally influenced by EGFR expression and
that erlotinib IC50 values are not correlated with EGFR protein expres-
sion, argue that off-targets can contribute to therapeutic efficacy.
Using a proteome-wide unbiased approach for determining drug tar-
gets [14], we detected several kinases targeted by erlotinib in PDAC
cells. STK10/LOK, MAP3K1, ILK, SLK, Ripk2, and ARG bind
to erlotinib with higher affinity than EGFR. Consistently, STK10/
LOK, SLK, RIPK2, and ARG were recently shown to bind to erlotinib
in an in vitro competition binding assay [28]. To our knowledge, no
data are currently available for expression or function of the STK10/
LOK and SLK kinases in PDAC. Consistent with our observations,
the tyrosine kinase activity of Ripk2 was recently shown to be inhibited
by erlotinib and gefitinib [29]. Ripk2 is upstream of NFκB signaling,
a pathway that can mediate proliferation and therapeutic resistance
of PDAC cells [30]. However, detailed analysis of RipK2 function in
PDAC is currently not available. High MAP3K1 expression was corre-
lated with tumor differentiation and lymph node metastasis in PDAC
[31]. Strong ILK expression is an independent prognostic factor in
PDAC patients after resection [32]. From the therapeutic view, ILK
was demonstrated to be involved in gemcitabine resistance of PDAC
cells [33,34]. Increased transcript levels of ARG were described in ap-
proximately 30% of PDACs [35]. Therefore, erlotinib targets several
kinases with well-documented expression and at least putative tumor-
relevant functions in PDAC. It would follow that a patient subpopu-
lation with tumors addicted to the expression of a kinase subset that is
efficiently inhibited by erlotinib, the erlotinib target kinome, responds
to therapy. Consistent with this, preclinical data from glioblastoma
multiforme, which is like PDAC characterized by the activation of mul-
tiple core signaling pathways, including the EGFR-pathway [36,37],
clearly demonstrate that several kinases must be efficiently targeted
to inhibit survival signaling and to induce a potent therapeutic re-
sponse [38]. In addition, a PDAC subset might exist, where survival
of the tumor cells is critically dependent on the activity of one kinase.
Figure 3. Target profiles of gefitinib and erlotinib. Shown are the
target proteins of erlotinib (A) and gefitinib (B) in dispersed primary
murine pancreatic cancer cells PPT6554. Kd values are plotted on a
logarithmic scale, and target proteins are ranked from low (top) to
high (bottom) Kd values. Protein kinases are depicted in blue; other
kinases, purple; associated proteins, orange; and other proteins,
green. Target proteins with Kd values lower than 10 μM are shown.
In addition, target proteins with Kd values greater than 10 μM are
indicated if they were identified as targets for both compounds. A
complete list of all target proteins is provided in Table W2.
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Interestingly, we observed that the erlotinib response of human T3M4
cells toward a clinically more relevant dose of 6 μM erlotinib [22,23]
depends in part on the presence of ARG. In addition to a wild-type
Kras status [39], T3M4 cells have higher ARG messenger RNA levels
than other human PDAC cell lines [35]. Furthermore, ARG is included
in a gene set that defines EGFR inhibitor responsiveness of PDAC [19].
However, we observed no correlation of the ARG protein expression
with the IC50 values of erlotinib in the 22 PDAC cell lines investigated,
which is consistent with the known tumor heterogeneity of PDAC and
argues that the dependency of the erlotinib response toward ARG is
Figure 4. Role of ARG in the erlotinib response of PDAC cells. MiaPaCa2 (A), BxPc3 (B), T3M4 (C), and PPT6554 (D) cells were trans-
fected with a control siRNA or an ARG-specific siRNA. Left panel: Knockdown of ARG 48 hours after the transfection by Western blot
analysis. β-Actin controls equal protein loading. Twenty-four hours after transfection, cells were treated with increasing doses of erlotinib
as indicated for 48 hours or were left as an untreated control. Viability was determined using MTT assays. Middle panel: Viability of control
siRNA-transfected cells was arbitrarily set to 100% and compared to (I) control siRNA-transfected and erlotinib-treated cells, to (II) ARG
siRNA-transfected cells, and to (III) ARG siRNA-transfected and erlotinib-treated cells. Right panel: Erlotinib-induced therapeutic response
in control and ARG siRNA-transfected cells. Note that the right panels rely on an extrapolation of the data presented in the middle panels
to better visualize the erlotinib-induced loss of viability (=therapeutic response) in control and ARG siRNA-transfected cells. Student’s
t test, *P < .05 versus controls.
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limited to a small PDAC subpopulation. Therefore, the contribution of
ARG toward the erlotinib response in PDAC awaits further preclinical
and clinical studies.
At the cellular level, ILK is located in focal adhesions, where the ki-
nase is part of the ILK-pinch-parvin (IPP) complex. The IPP complex
functions to connect integrins to the actin cytoskeleton and acts as a
signaling hub to direct various processes, such as proliferation, motility,
or invasion [40]. In addition to ILK, we detected the IPP components
LIMS1 (PINCH1), parvin-α, and parvin-β recruited by erlotinib.
However, the contribution of the IPP complex function in the erlotinib
Figure 5. Tyrosine phosphorylation of ARG is reduced on erlotinib treatment. (A) T3M4 cells were treated with erlotinib as indicated or
were left as an untreated control. After 20 minutes, whole-cell extracts were prepared, and ARG was immunoprecipitated. Pre–immune
IgGs were used as precipitation controls. Western blots were performed with ARG and anti–phosphotyrosine antibodies. The input (5%)
was probed with ARG and anti–phosphotyrosine antibodies. (B) Western blot analysis of ARG protein expression levels in the indicated
PDAC cell lines. β-Actin controls equal protein loading. (C) Correlation of the erlotinib IC50 values with the ARG protein expression in
22 PDAC cell lines. The Spearman correlation coefficient and the P value (two-tailed) are indicated. T3M4 cells are depicted as a red
box. MiaPaCa2 (D), BxPc3 (E), T3M4 (F), and PPT6554 (G) were treated with imatinib as indicated or with vehicle as control. Viability was
determined after 48 hours using MTT assays. Imatinib IC50 values and the 95% confidence interval (95% CI) are indicated.
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response awaits further investigation. In addition, the impact of the
nonprotein kinase proteins bound by erlotinib toward the erlotinib
response is unclear now.
In addition to erlotinib, cetuximab, a monoclonal antibody directed
against EGFR, was investigated in a large phase 3 trial in combination
with gemcitabine in patients with locally advanced or metastatic
PDAC [41]. Here and in contrast to the erlotinib/gemcitabine trial
[6], no significant difference in median survival in the cetuximab/
gemcitabine arm compared to gemcitabine monotherapy was ob-
served [41]. Therefore, the erlotinib off-targets may explain the dis-
crepant outcomes.
Consistent with our data, a recent report demonstrated that erlotinib,
in contrast to gefitinib, potently inhibited STK10/LOK [42]. By inhib-
iting STK10/LOK, erlotinib can activate lymphocytes and exacerbate
experimental skin inflammation in vivo [42]. Because lymphocytes
are known to be involved in EGFR inhibitor–induced skin toxicity,
the authors propose a contribution of STK10/LOK in this process
[42]. Whether STK10/LOK or lymphocytes activated via STK10/
LOK inhibition are involved in the therapeutic response on erlotinib
treatment in human PDAC awaits further investigations.
In addition to the direct inhibition of erlotinib target kinases, rather
indirect mechanisms can contribute to the sensitivity of PDAC cells
toward erlotinib. For instance, erlotinib sensitivity of PDAC cells
was recently shown to depend on the heterodimerization of the EGFR
with ErbB3 [21]. However, the relevance of such mechanisms in
clinical settings is unclear in the moment.
In summary, we demonstrate that erlotinib targets several kinases in
PDAC with higher affinity than the EGFR and should therefore be
considered as a multikinase inhibitor. We suggest two possibilities
that characterize erlotinib responding PDAC cells: (I) high expression
and/or functional relevance of a kinase subset efficiently inhibited by
erlotinib or (II) addiction of the PDAC tumor cells to one kinase in
the target spectrum of erlotinib. Whereas the relevance of these two
possibilities in clinical settings is unclear at the moment and we cannot
exclude the possibility that due to the wide heterogeneity of PDAC,
none of the described erlotinib targets might predict erlotinib respon-
siveness. Our data may influence monitoring of future erlotinib trials to
identify relevant erlotinib-responding subpopulations and to better
stratify clinical trials and therapy.
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Supplemental Materials and Methods
Compound Synthesis and Immobilization
Erlotinib hydrochloride salt (Tarceva, OSI-774) and gefitinib free base
(Iressa, ZD1839) were purchased from LC Laboratories (Woburn, MA).
AX14596 (linker-gefitinib) was synthesized as described [1]. Synthesis of
KX214 (6-amino-propoxy-linked 4-anilinoquinazoline) (linker-erlotinib):
The following schedule gives a short schematic overview about the
synthetic route, which afforded the designated amino-propoxy–linked
erlotinib-derivative 8:
The synthesis of compound 8 was performed by the application of
a modified published synthetic procedure [2], starting with a base-
promoted O-alkylation of methyl 3-hydroxy-4-methoxy-benzoate 1
with N -(3-bromopropyl)-phthalimide to give amino-protected inter-
mediate 2. Afterward, nitration and reduction of 2 afforded sub-
sequently nitro-derivative 3 and methyl-2-amino-benzoate derivative 4,
respectively, and cyclization of 4 in the presence of formamide and
ammonium formate yielded the key quinazoline-derivative 5.
Thereafter, 5 was treated with POCl3 and a catalytical amount
of N ,N -dimethylaniline at 120°C and consecutive SN,Ar reaction
with 3-aminophenylacetylene converted 6 to the amino-protected
4-anilinoquinazoline 7. Finally, 7 underwent smoothly cleavage of
the phthalimide functionality under basic conditions to release the free
6-amino-propoxy–linked 4-anilinoquinazoline 8.
High-performance liquid chromatography–mass spectrometry (HPLC)
and nuclear magnetic resonance spectroscopy (NMR) final analyses were
performed with the following equipment and methods:
HPLC-MS.
Varian: 1200 L Triple Quadrupole mass spectrometer
Ionization mode: +ESI
UV-Detector: ProStar 325 (254 nm)
HPLC column: Varian Polaris C18 (length = 100 mm, diameter =
3 mm, particle size = 3 μm)
HPLC method:
Mobile phase: acetonitrile/water + 0.1% HCOOH
Run time: 9.50 minutes
Gradient: acetonitrile content was raised from 10% to 90% in
3 minutes
NMR.
Varian: Oxford NMR 400
1H: 400.00 MHz
The sampleswere solved inCDCl3or dimethyl sulfoxide (DMSO)-d6.
Trimethylsilane was used as internal standard.
HPLC (preparative).
HPLC column: Varian RP Polaris C18 (length = 250 mm, diam-
eter = 21.4 mm, particle size = 5 μm)
Mobile phase: acetonitrile/methanol + 0.1% HCOOH
Synthesis of 2. Amixture of 0.2 g (0.0011 mol) of methyl 3-hydroxy-
4-methoxy-benzoate, 0.45570 g (0.0017 mol) of N -(3-bromopropyl)-
phthalimide, and 0.235 g (0.0017 mol) of sodium carbonate in 6 ml
of DMF was stirred for 2 hours under reflux. The reaction mixture was
a) N -(3-bromopropyl)phthalimide, K2CO3, dimethylformamide (DMF), reflux; b) AcOH, HNO3, H2SO4, room temperature; c) SnCl2, ethyl acetate, H2O,
reflux; d) NH4CHO2, formamide, 140°C; e) POCl3, N ,N -dimethylaniline (DMA), 120°C; f ) 3-aminophenylacetylene, chlorobenzene, 120°C; g) hydrazine
hydrate, MeOH, room temperature.
Table W1. Genotype of Murine Cell Lines.
Cell Line Genotype
Murine PDAC cell lines
W22 Ptf1aCre/+;LSL-KrasG12D/+;p53loxP/lox;R26 LSL-TVA-LacZ/+
PPT6554 Ptf1aCre/+;LSL-KrasG12D/+;p53loxP/loxP;R26 LSL-TVA-LacZ/+
PPT6556 Ptf1aCre/+;LSL-KrasG12D/+;p53loxP/+;LSL-p53R172H/+
PPT6558 Ptf1aCre/+;LSL-KrasG12D/+;p53loxP/+;LSL-p53R172H/+;R26 LSL-TVA-LacZ/+
W30 Ptf1aCre/+;LSL-KrasG12D/+;p53loxP/+
PPT15272 Ptf1aCre/+;LSL-KrasG12D/+
PPT53268 Ptf1aCre/+;LSL-KrasG12D/+
PPT16992 Ptf1aCre/+;LSL-KrasG12D/+;R26 LSL-TVA-LacZ/+
PPT53631 Ptf1aCre/+;LSL-KrasG12D/+
PPT6051 PDX1-Cre;LSL-KrasG12D/+;LSL-p53R172H/+
PPT3202 Ptf1aCre/+;LSL-KrasG12D/+;LSL-PCNA-Luc
PPT5436 Ptf1aCre/+;LSL-KrasG12D/+;LSL-p53R172H/R172H;R26 LSL-TVA-LacZ/LSL-TVA-LacZ
PPT3107 Ptf1aCre/+;LSL-KrasG12D/+;LSL-p53R172H/+;R26 LSL-TVA-LacZ/+
ASC53909 Ptf1aCre/+;LSL-KrasG12D/+;R26 LSL-TVA-LacZ/+
evaporated to dryness and the residue was dissolved in 20 ml of
dichloromethane (DCM). The organic phase was washed with water
and brine and finally dried over MgSO4. Evaporation of the solvent
under reduced pressure afforded the crude product, which was used
for the following conversions without further purification.
Yield: 0.312 g (76.6%).
1H NMR (CDCl3, 400 MHz): 2.22–2.28 (m, 2H), 3.62 (s, 3H),
3.87 (s, 3H), 3.93 (t, 3J = 8 Hz, 2H), 4.14 (t, 3J = 2.4 Hz), 6.81 (d,
3J = 4 Hz, 1H), 7.51 (d, 4J = 2 Hz, 1H), 7.63–7.66 (m, 1H), 7.69–
7.72 (m, 2H), 7.82–7.84 (m, 2H).
MS (ESI): m/z = 392 [M + Na]+.
Synthesis of 3. The amount of 10.56 ml of nitric acid and 12.31 ml
of sulfuric acid at 0°C were dropwise added to a solution of 11,644 g
(0.0315 mol) of 2 in 200 ml of acetic acid. After 1.5 hours of stirring
at room temperature, the mixture was poured in 500 ml of H2O at
0°C and extracted with 3 × 400 ml of DCM. The combined organic
phases were washed with saturated Na2CO3(aq) and dried over
MgSO4. Evaporation of the solvent under reduced pressure afforded
the crude product, which was used for the following conversions
without further purification.
Yield: 10.48 g (80.2%).
1H NMR (CDCl3): 2.25–2.31 (m, 2H), 3.69 (s, 3H), 3.89 (s,
3H), 3.93 (t, 3J = 6,4 Hz, 2H), 4.18 (t, 3J = 5,6 Hz, 2H), 7.01
(s, 1H), 7.35 (s, 1H), 7.72–7.73 (m, 2H), 7.81–7.86 (m, 2H).
MS (ESI): m/z = 437 [M + Na]+.
Synthesis of 4. The amount 3.66 g (0,0193 mol) of tin chloride
and 10 ml of water were subsequently added to a solution of 2 g
(0.0048 mol) of 3 in 200 ml of ethyl acetate. After stirring for 1 hour
under reflux, the heterogeneous mixture was diluted with 300 ml of
ethyl acetate, and a resulting precipitate was removed by filtration. The
organic phase was washed with saturated NaHCO3(aq) and dried over
MgSO4. After removal of the solvent at reduced pressure, the desired
product was purified and isolated by flash chromatography (silica,
EE/H 1:1; 0.33).
Yield: 0.95 g (51.59%).
MS (ESI): m/z = 385 [M + 1]+, 407 [M + Na]+.
Synthesis of 5. The amount of 0.237 g (0.0038 mol) of ammo-
nium formate was added to a solution of 0.853 g (0.0022 mol) of
4 in 50 ml of formamide, and the mixture was stirred for 12 hours at
140°C. The reaction progress was monitored by HPLC, and after
quantitative conversion, 100 ml of H2O was poured to the organic
solution, which conducted the formation of a beige precipitate. The
solid was filtered off and washed subsequently with 50 ml of H2O
and 50 ml of ether. The isolated solid was dried in high vacuo, and
the crude product was used in the following conversions without fur-
ther purification.
Yield: 0.384 g (45.59%).
MS (ESI): m/z = 380 [M + 1]+.
Synthesis of 6. The amount of 1.93 ml (0,0027 mol) of N ,N -
dimethylaniline was dropwise added at 0°C to a solution of 2.127 g
(0.0056 mol) of 5 in 10 ml of phosphorus oxychloride. After being
stirred at room temperature for a further 5 minutes, the mixture was
heated under reflux for additional 12 hours. Afterward, the mixture
was poured into 50 ml of H2O at 0°C, which induced precipitation
of the demanded compound 6. Filtration and washing with cold
H2O and finally with ether afforded compound E in satisfactory purity,
and the crude product was used in the following conversions without
further purification.
Yield: 1.77 g (79.53%).
MS (ESI): m/z = 398 [M + 1]+.
Synthesis of 7. A mixture of 1.774 g (0.0045 mol) of 6 and 0.783 g
(0.0045 mol) of 3-aminophenylacetylene in 15 ml of chlorobenzene
was stirred for 2 hours at 120°C. The maintaining precipitate was
filtered off and subsequently washed with chlorobenzene, H2O, and
finally with ether. Removal of traces of solvent by high vacuo afforded
the required compound 7, which was applied in the following conver-
sions without further purification.
Yield: 1.712 g (79.53%).
MS (ESI): m/z = 479 [M + 1]+.
Synthesis of 8. The amount of 0.020 g (0.0004 mol) g of hydrazine
hydrate was added to a solution of 0.0654 g (0.00014 mol) of 7 in 4 ml
of MeOH, and the mixture was stirred at ambient temperature. The
reaction progress was monitored by HPLC, and after quantitative
conversion, the reaction mixture was evaporated to dryness. The re-
maining residue was dissolved in 10 ml of DCM, washed with brine,
and dried over MgSO4. After removal of the solvent at reduced pres-
sure, the product was purified by flash chromatography (silica, DCM/
MeOH 4:1).
Yield: 20.7 mg (43.0%).
1H NMR (D2O): 2.19–2.22 (m, 2H), 3.30–3.31 (m, 2H), 3.51
(s, 1H), 3.98 (s, 3H), 4.30 (t, 3J = 8,0 Hz, 2H), 7.10 (s, 1H), 7.23
(d, 2J = 7,6 Hz, 1H), 7.35 (t, 3J = 9,3 Hz, 1H), 7.68–7,77 (m, 2H),
7.87–8.0 (m, 1H), 8.41 (s, 1H).
MS (ESI): m/z = 349 [M + 1]+.
For immobilization, drained epoxy-activated Sepharose 6B (GE
Healthcare, Pittsburgh, PA) was resuspended in 2 volumes of 5 mM
AX14596 or 5 mM linker-erlotinib dissolved in 50% DMSO/
25 mM Na2CO3 and incubated with permanent agitation overnight
at 30°C in the dark. Beads were washed with 50% DMSO/25 mM
Na2CO3, and remaining active groups were blocked with 1 M ethanol-
amine. Subsequent washing steps were performed according to the
manufacturer’s instructions. To generate the control matrix, epoxy-
activated Sepharose 6B was incubated with 1 M ethanolamine and
treated as described above. The concentration of covalently immobilized
inhibitor was determined spectrophotometrically by measuring the
reduction of the inhibitor concentration in the soluble phase during
the coupling reaction. EAH-Sepharose (GE Healthcare) was used as
a negative control. The beads were stored at 4°C in the dark.
In Vitro Association Experiments
For SILAC, low-passaged (P4) primary dispersed murine pancreatic
carcinoma cells from the primary PDAC of a Ptf1aCre/+;LSL-KrasG12D;
p53lox/lox mouse (#6554) (PPT6554) were cultivated as described pre-
viously [3,4]. For in vitro association experiments, PPT6554 cells were
lysed in buffer containing 20 mM HEPES pH 7.5, 400 mM NaCl,
0.25% Triton X-100, 3 mM MgCl2, 1 mM EDTA, 1 mM EGTA,
80 U/ml Benzonase plus additives (10 μg/ml aprotinin, 10 μg/ml
leupeptin, 1 mM PMSF, 1 mM Na3VO4, 10 mM NaF). After centri-
fugation, lysates were adjusted to 1 M NaCl and filtered through a
0.45-μm cellulose acetate filter before in vitro association of 750 μl of
lysate containing 3 mg of protein with either 30 μl of drained inhibitor
or control matrix for 2.5 hours at 4°C. Incubation procedures were per-
formed essentially as described previously [4], with the addition that
inhibitor beads representing five different compound densities were
incubated with the cell extract to determine binding curves for each
identified protein. For competition experiments, SILAC-encoded
cell extracts were treated with different concentrations of erlotinib
(0 nM, 10 nM, 100 nM, 300 nM, 1 μM, 10 μM, and 50 μM)
or gefitinib (0 nM, 10 nM, 100 nM, 300 nM, 1 μM, 10 μM, and
100 μM) for 30 minutes before addition of inhibitor beads and in-
cubation for an additional 2.5 hours at 4°C. In all in vitro association
experiments, subsequent washing and elution steps including the sep-
aration of proteins by electrophoresis and the in-gel digest with trypsin
were performed as described previously [4].
Mass Spectrometric Analysis
Mass spectrometric analysis of the labeled and combined peptide
fractions was carried out by online nanoLC-MS/MS [4]. Samples were
loaded directly by an Agilent 1200 nanoflow system (Agilent Tech-
nologies, Santa Clara, CA) on a 15-cm fused silica emitter (New
Objective) packed in-house with reversed phase material (Reprusil-
Pur C18-AQ, 3 μm; Dr. Maisch GmbH) at a flow of 500 nl/min.
Bound peptides were eluted by a gradient from 2% to 40% solvent B
(80% ACN and 0.5%HOAc) at a flow rate of 200 nl/min and sprayed
directly into an LTQ-Orbitrap XL mass spectrometer (Thermo Fischer
Scientific, Waltham, MA) at a spray voltage of 2 kV using a nano-
electrospray ion source (Proxeon Biosystems, Dreieich, Germany).
The mass spectrometer was operated in the positive ion mode and a
data-dependent switch between MS and MS/MS acquisition. To im-
prove mass accuracy in theMSmode, the lock-mass option was enabled
[5]. Full scans were acquired in the Orbitrap at a resolution R = 60 000
and a target value of 1,000,000 charges. The five most intense ions
detected in the MS were selected for collision-induced dissociation at
a target value of 5000, and the resulting fragmentation spectra were
recorded in the linear ion trap. Ions that were once selected for data-
dependent acquisition were dynamically excluded for 30 seconds for
further fragmentation.
Data Analysis
Mass spectra were processed using the MaxQuant software version
1.0.12.28 [6], using the Mascot search engine (version 2.2.0) for pep-
tide and protein identification. A concatenated forward and reversed
IPI mouse database (version 3.39) was used comprising 106,658 data-
base entries. Regarding the search parameters, the minimal peptide
length was set to six amino acids, trypsin was selected as the proteo-
lytic enzyme, and maximally two missed cleavage sites were allowed.
Carbamidomethylation of cysteine residues was selected as a fixed
modification, whereas methionine oxidation and N-terminal protein
acetylation were allowed as a variable modification. Because MaxQuant
automatically extracts isotopic SILAC peptide triplets, the corre-
sponding isotopic forms of lysine and arginine were automatically se-
lected for database search as fixed modifications. The maximal mass
deviation of precursor and fragment masses was set to 7 ppm and
0.5 Da. A false discovery rate of 0.01 was selected for proteins and
peptides, and a posterior error probability (PEP) below or equal to
0.1 for each MS/MS spectrum was required. Target-specific dissocia-
tion constants for the tested free kinase inhibitors were calculated based
on SILAC quantification data using the Cheng-Prusoff equation as
described previously [7].
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